单次腔内灌注吡柔比星预防浅表性膀胱癌术后复发  

Single bladder pirarubicin perfusion to prevent the recurrence of superficial bladder carcinoma

作　　者：彭健[1] 潘敏[1] 

机构地区：[1]北京大学深圳医院泌尿外科,518000

出　　处：《现代泌尿生殖肿瘤杂志》2011年第3期157-158,共2页Journal of Contemporary Urologic and Reproductive Oncology

摘　　要：目的通过对吡柔比星单次与多次灌注预防浅表性膀胱癌术后复发的对比研究,探讨临床应用吡柔比星单次腔内灌注预防浅表性膀胱癌术后复发的可行性。方法将42例浅表性膀胱癌患者随机分为两组。A组(22例)患者术后即刻单次灌注吡柔比星50mg;B组(20例)术后定期灌注吡柔比星30mg至术后半年。随访3年,观察两组肿瘤复发率及不良反应发生情况。结果肿瘤复发情况:A组3例复发;B组4例复发。两组间复发率差异无统计学意义(P>0.05)。不良反应发生情况:A组无一例不良反应发生;B组20例均有不同程度不良反应发生,其中4例较重。两组间不良反应发生率差异有统计学意义(P<0.05)。结论吡柔比星单次腔内灌注预防浅表性膀胱癌术后复发作用可靠,且无不良反应发生。Objective To determine the feasibility of single bladder pirarubicin perfusion in the prevention of recurrent superficial bladder carcinoma by matched control of single and multiple bladder pirarubicin perfusions.Methods 42 postoperative patients with superficial bladder carcinoma were randomized into two groups.Group A（22 patients）were received 50 mg single pirarubicin perfusion after operation immediately.Group B（20 patients）were received 30 mg regular pirarubicin perfusion after operation until half a year.Two groups were followed up for tumor recurrent rate and adverse reactions for 3 years.Results The recurrent rate：Group A had 3 patients.Group B had 4 patients.The recurrent rates between the two groups were found no significant difference（P〉0.05）.The adverse reaction：Group A had none.Group B had 20 patients who appeared adverse reactions to a certain extent.There were 4 patients who appeared serious among those.The adverse reactions between the two groups had significant difference（P〈0.05）.Conclusions Single bladder pirarubicin perfusion immediately after tumor resection has stable effect in the prevention of superficial bladder cancer recurrence and no adverse reactions.

关 键 词：膀胱肿瘤 化学疗法 肿瘤 局部灌注 肿瘤复发 局部 吡柔比星 

分 类 号：R737.14[医药卫生—肿瘤]